

1 Detecting tandem repeat expansions in cohorts sequenced with short-read 2 sequencing data

3

4 Rick M Tankard^{1,2,3}, Mark F Bennett^{1,2}, Peter Degorski,^{1,2} Martin B Delatycki,^{4,5,6}
5 Paul J Lockhart,^{4,6†} Melanie Bahlo^{1,2* †}

6

7 ¹ Population Health and Immunity Division, The Walter and Eliza Hall Institute of
8 Medical Research, Parkville 3052, VIC, Australia

9 ² Department of Medical Biology, The University of Melbourne, Melbourne 3010,
10 VIC, Australia

11 ³ Mathematics and Statistics, Murdoch University, Murdoch 6150, WA, Australia

12 ⁴ Bruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research
13 Institute, Royal Children's Hospital, Parkville, Victoria, Australia.

14 ⁵ Victorian Clinical Genetics Services, Parkville, Victoria, Australia.

15 ⁶ Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia.

16

17

18 [†] Joint senior authors

19 * Corresponding Author: Melanie Bahlo, bahlo@wehi.edu.au, twitter handle
20 @MelanieBahlo

21

22 **Keywords:** next-generation sequencing; repeat expansion disorders; short tandem
23 repeats; whole exome sequencing; whole genome sequencing

24

25 **Abstract**

26 Repeat expansions cause over 30, predominantly neurogenetic, inherited
 27 disorders. These can present with overlapping clinical phenotypes, making molecular
 28 diagnosis challenging. Single gene or small panel PCR-based methods are employed
 29 to identify the precise genetic cause, but can be slow and costly, and often yield no
 30 result. Genomic analysis via whole exome and whole genome sequencing (WES and
 31 WGS) is being increasingly performed to diagnose genetic disorders. However, until
 32 recently analysis protocols could not identify repeat expansions in these datasets.

33 A new method, called exSTRa (**expanded Short Tandem Repeat algorithm**)
 34 for the identification of repeat expansions using either WES or WGS was developed
 35 and performance of exSTRa was assessed in a simulation study. In addition, four
 36 retrospective cohorts of individuals with eleven different known repeat expansion
 37 disorders were analysed with the new method. Results were assessed by comparing to
 38 known disease status. Performance was also compared to three other analysis methods
 39 (ExpansionHunter, STRetch and TREDPARSE), which were developed specifically
 40 for WGS data. Expansions in the STR loci assessed were successfully identified in
 41 WES and WGS datasets by all four methods, with high specificity and sensitivity,
 42 excepting the FRAXA STR where expansions were unlikely to be detected. Overall
 43 exSTRa demonstrated more robust/superior performance for WES data in comparison
 44 to the other three methods. exSTRa can be applied to existing WES or WGS data to
 45 identify likely repeat expansions and can be used to investigate any STR of interest,
 46 by specifying location and repeat motif. We demonstrate that methods such as
 47 exSTRa can be effectively utilized as a screening tool to interrogate WES data
 48 generated with PCR-based library preparations and WGS data generated using either
 49 PCR-based or PCR-free library protocols, for repeat expansions which can then be

50 followed up with specific diagnostic tests. exSTRa is available via GitHub
51 (<https://github.com/bahlolab/exSTRa>).

52

53 **Introduction**

54 Thousands of short tandem repeats (STRs), also called microsatellites, are scattered
55 throughout the human genome. STRs vary in size but are commonly defined as
56 having a repeat motif 2-6 base pairs (bps) in size. They are underrepresented in the
57 coding regions of the human genome¹, despite the vast majority being population
58 polymorphisms with no, or very little, phenotypic consequence. STRs were used as
59 genetic markers for linkage mapping for human studies for many years, and continue
60 to be used, but primarily for non-human studies. A subset of STRs can however cause
61 disease. Pathogenic STRs have either one or two alleles, depending on the genetic
62 model, that exceed some threshold for biological tolerance. These diseases are known
63 as repeat expansion disorders. The abnormal STR allele(s), may affect gene
64 expression levels, cause premature truncation of the protein or result in aberrant
65 protein folding.² Repeat expansions at different STR loci share biological
66 consequences. Common disease mechanisms mediated by repeat expansion disorders
67 include Repeat-associated non-AUG translation and MBNL spliceosome interference,
68 for example caused by CUG expansions in Myotonic Dystrophy Type 1 (DM1).
69 These mechanisms are reviewed in Hannan³.

70

71 Repeat expansions cause ~30 inherited germline human disorders, predominantly
72 neurogenetic diseases most often presenting with ataxia as a clinical feature. The size
73 of pathogenic allele varies from ~60 repeats observed in the gene encoding the
74 Calcium Voltage-Gated Channel Subunit Alpha1 A (CACNA1A) to several thousand

75 repeats observed in the gene encoding the Calcium Voltage-Gated Channel Subunit
76 Alpha1 A (*C9orf72*) (Table 1). Remarkably 12 repeat expansions have now been
77 identified as causing dominant forms of spinocerebellar ataxias. Other disorders
78 caused by repeat expansions include fragile X syndrome (OMIM #300624, a repeat in
79 the 5'UTR of *FMR1*), Huntington Disease (OMIM #606438, a repeat in exon 1 of
80 *HTT*), myotonic dystrophy (OMIM #602668, repeats in *DMPK* and *ZNF9*), fronto-
81 temporal dementia and amyotrophic lateral sclerosis 1 (OMIM #105550, a 6-mer
82 repeat in *C9orf72*) and Unverricht-Lundborg disease, a severe myoclonic epilepsy
83 (OMIM #254800, in *CSTB*). The genetic mode of inheritance encompasses autosomal
84 dominant (e.g. SCA1, OMIM #164400) and recessive (e.g. Friedreich ataxia, OMIM
85 #229300), as well as X-linked recessive (e.g. fragile X syndrome, OMIM #300624).
86 Novel pathogenic alleles underlying repeat expansion disorders continue to be
87 discovered, with the two most recently described STRs being pentamer repeats^{4; 5}. A
88 selected list of repeat expansion disorders are shown in Table 1.

89

90 Many repeat expansion disorders show anticipation; a phenomenon whereby younger
91 generations are affected by earlier age of onset. Anticipation is usually caused by an
92 increase in repeat size between generations. When anticipation is observed it indicates
93 that a search for repeat expansions as the cause of disease is warranted.

94

95 Friedreich ataxia is the most common of the recessive repeat expansion disorders,
96 with a disease prevalence of 3 to 4/100,000 but with a carrier frequency of 1/100.⁶
97 Fragile X syndrome is the most common cause of inherited intellectual disability and
98 affects ~1/5000 individuals.^{7; 8} Hence these diseases as a whole contribute
99 significantly to the overall Mendelian disease burden in human populations.

100

101 Diagnostic identification of repeat expansions can be time consuming and costly.
 102 Current medical diagnosis consists of precise PCR or Southern blot assay, which
 103 require diagnostic laboratories that have refined these assays for each different repeat
 104 expansion. The clinician has to determine which repeat expansions are most likely to
 105 be relevant and submit the patient's DNA to appropriate laboratories. This can be
 106 difficult, given the phenotypic overlap between the different STRs, the potential
 107 heterogeneity in the symptoms and the variation in penetrance and age of onset,
 108 which is also dependent on the size of the allele and effect of modifier genes.^{9; 10} In
 109 addition, up to 50% of individuals with a diagnosis of ataxia may be due to other
 110 mutation types, such as single nucleotide variants (SNVs) and short
 111 insertion/deletions (indels).¹¹ Therefore, molecular diagnosis of these disorders often
 112 also requires conventional sequencing of candidate genes, either by Sanger, targeted
 113 panel or Next Generation Sequencing (NGS) methods.

114

115 Short-read NGS data, such as that generated by the Illumina sequencing platform, is
 116 currently predominant in both research and clinical diagnostic applications. Moreover,
 117 Whole Genome Sequencing (WGS) is now an affordable technology, gradually
 118 replacing whole exome sequencing (WES) for clinical genomics. Illumina's HiSeq X
 119 and NovaSeq platforms are currently the most commonly used platform for the
 120 generation of human WGS data and in particular clinical human genome sequencing
 121 with low error rates and well-documented, consistent, performance.

122

123 Illumina HiSeq X data reads are 150 bp in length and are designed so that the reads
 124 are transcribed facing each other, where the template DNA predominantly has a small

125 gap between the reads that is not sequenced. This gap can vary in size, but standard
126 library preparation methodologies generate insert fragment lengths of ~350 bps,
127 resulting in a gap of ~50bp.

128

129 Standard clinical diagnostic pipelines focus on the identification of SNVs and indels.
130 Bioinformatic tools have been developed to genotype STRs, but are almost entirely
131 confined to those STR alleles that are spanned by reads.¹²⁻¹⁶ Pathogenic repeat
132 expansions are usually significantly longer than the reads generated by short-read
133 sequencing platforms such as Illumina, and may be longer than the library insert
134 fragments lengths. Therefore, the short reads cannot span many pathogenic repeat
135 expansion alleles, such as those that cause SCA2 (OMIM #183090), or SCA7 (OMIM
136 #164500, Table 1). Furthermore some of these reads are not mapped, or poorly
137 mapped, to the STR allele, due to sequencing bias and alignment issues such as: (i)
138 the repetitive nature of the repeat itself where the expanded alleles require alignments
139 of additional repetitive bases, (ii) multiple occurrences of the same repeat throughout
140 the genome, leading to multi-mapping reads, and (iii) GC bias. Despite this, these data
141 do still carry information about the expanded allele with a larger number of reads
142 mapping to the STR for an expanded allele than expected, based on the reference STR
143 allele lengths.

144

145 Several methods now describe the detection of repeat expansion in short read NGS
146 data. These include ExpansionHunter¹⁷, STRetch¹⁸ and TREDPARSE¹⁹, reviewed in
147 Bahlo et al²⁰. These methods are focused on detection of repeat expansions in whole
148 genome sequencing data, with a preference for PCR-free library free protocols.
149 ExpansionHunter and TREDPARSE determine whether an individual has an

expansion based on pre-determined thresholds, however TREDPARSE also has a likelihood ratio test with a likelihood framework that determines the genetic model and the likelihood of expansion. STRetch uses a genome reference augmented with decoy chromosomes, consisting of long stretches of all 1 to 6 bp repeat expansions to competitively attract long repeats. None of these methods have been assessed for performance in comparison to each other or in WES data.

Here we describe the development of the STR repeat expansion-calling algorithm, exSTRa (**ex** expanded **STR** algorithm), which detects expanded repeat expansion allele(s) at repeat expansion loci, specified by the user, in cohorts of sequenced individuals. We demonstrate the utility of the method with twelve different verified repeat expansion disorders. exSTRa is designed to be applied to cohorts of individuals without requiring a set of controls. This is because exSTRa is designed as an outlier detection test, where the majority of individuals (>85%) are assumed to have normal length alleles at a particular repeat expansion locus. This assumption is robust for the majority of disease cohorts, even spinocerebellar ataxias. exSTRa also generates unique empirical cumulative distribution function (ECDF) plots of individual's repeat motif distributions, plotted for all individuals in a cohort, facilitating QC for batch effects and validity of assumptions. We demonstrate for the first time, that repeat expansion detection is possible with WES data and further demonstrate on additional STR loci, that PCR-based library preparation WGS, whilst inferior to PCR-free library preparation WGS data, can be used to confidently interrogate most known STR loci. This will enable researchers to interrogate the thousands of existing NGS datasets for repeat expansions at known repeat loci or any other loci they wish to investigate.

175

176 **Methods**

177 **Study cohorts and next-generation sequencing data generation**

178 Individuals with already diagnosed repeat expansion disorders were recruited for this
179 study. The repeat expansion status was verified via standard diagnostic STR-specific
180 PCR-based assays. Individuals affected by neurogenetics disorders not due to known
181 repeat expansions were recruited as controls. These individuals were not tested for
182 any of the known repeat expansion loci with standard methods as none of them are
183 affected by symptoms that are typical of expansion disorders such as ataxia. All
184 individuals were recruited at the Murdoch Children's Research Institute, and provided
185 written informed consent (Human Research Ethics Committee #28097, #25043 and
186 #22073).

187

188 Four cohorts underwent different types of NGS, with some individuals being
189 sequenced multiple times. Individuals were sequenced with either: (i) WES with the
190 Agilent V5+UTR capture platform (4 repeat expansion patients, with 4 different
191 expansion disorders, 58 controls), (ii) WGS with the TruSeq Nano protocol, which
192 includes a PCR step to increase sequencing material (17 repeat expansion patients,
193 with 8 different expansion disorders, 16 controls), or (iii) WGS with the PCR-free
194 cohort consisting 118 individuals (52 females and 66 males). Samples in this cohort
195 were either affected with the repeat expansion disorder, or carriers, for one of:
196 FRAXA (15 expanded, 19 intermediate), FRDA (25), DM1 (17), HD (13), SCA1 (3),
197 DRPLA (2), SBMA (1) and SCA3 (1), or relatives with no known expansion (22),
198 with all samples sourced from the Coriell resource. The WES cohort is designated as
199 WES_PCR. Two different cohorts were sequenced with protocol (ii). These are

200 designated as WGS_PCR_1 and WGS_PCR_2. The WGS cohort was designated as
201 WGS_PF. These cohorts are described in Table 2.

202

203 **Sequencing Data generation**

204 WGS data with PCR (WGS_PCR1 and WGS_PCR2) was generated by the Kinghorn
205 Centre for Clinical Genomics, Garvan Institute of Medical Research, Sydney,
206 Australia with HiSeq X Ten. The WES data (WES_PCR) was generated by the
207 Australian Genome Research Facility, Melbourne, Australia, and sequenced on a
208 HiSeq 2500 sequencer. All WGS_PF samples were sequenced on the Illumina HiSeq
209 X sequencing platform at Illumina, La Jolla, California, USA. Further details can be
210 found in Dolzhenko et al. All sequencing data was aligned to the hg19 human genome
211 reference using the Bowtie 2 aligner²¹ in local alignment mode.

212

213 **Definition of Repeat Expansion Loci**

214 Table 1 defines the chromosomal location, physical map location, disease, genetic
215 disease model and repeat motif, normal and repeat expansion size for 24 repeat
216 expansion loci, which cause neurological disorders. For the analyses in this paper we
217 examined 21 of these STR loci, excluding the more recently discovered SCA37 and
218 FAME1 loci, and the SCA31 locus, where the inserted repeat is not in the reference
219 sequence. This focused the analysis on currently most likely tested expansion loci and
220 in particular concentrating on the spinocerebellar ataxia repeat expansion loci.

221

222 **Data extraction for repeat expansions**

223 We developed a two-step analysis method, called exSTRa, detailed in the
224 Supplemental data, to identify individuals likely to have a repeat expansion at a

particular STR locus. The analysis method extracts STR repeat content information for each read, stemming from a particular individual, which has been identified as mapping to one of the 21 STR loci. We designed a statistical test that captures the differences between an individual to be tested within a cohort of cases and controls. All N individuals within a cohort are examined in turn at each of the 21 known pathogenic repeat expansion loci by comparing each individual in turn to all N other individuals in each cohort. This generates 21xN test statistics per cohort. The empirical p-value of the test statistic was determined using a simulation method. All p-values over all STR loci for all individuals within each cohort were assessed for approximate uniform distribution with histograms and Quantile-Quantile (Q-Q) plots.

Raw data was visualized using empirical cumulative distribution functions (ECDFs), which display the distribution of the amount of STR repeat motif found in each read, ordered from smallest to largest content amount, as a step function. This allows comparison of the distributions, regardless of sequencing depth. Reads generated from expanded alleles have increased numbers of repeat motifs in their reads compared to reads stemming from normal alleles. This produces a shift of the read repeat motif distribution to the right for the individual with the repeat expansion, in comparison to reads from individuals with normal alleles.

Simulation Study

We conducted a simulation study using the next generation sequencing data simulation package ART²², which simulates NGS data with realistic error profiles based on supplied reference genomes. Alleles at STR loci were simulated using reference genomes where alleles (normal, intermediate, expanded) had been inserted

250 into the reference genome. STR loci such as HD do not have an intermediate range or
 251 only a very narrow range. We extensively searched the literature to determine
 252 pathogenic and non-pathogenic ranges of STR length alleles. We only used the
 253 ‘overall’ distribution, ignoring any ethnic specificity for these loci. We did not apply a
 254 stutter model in the simulations, as this was not feasible due to ARTs constraints. We
 255 simulated data for 20 STR loci (excluding FAME1, SCA31, SCA37 and SCA31), for
 256 200 controls, and ten normal, ten intermediate range and ten expanded individuals.
 257 These 30 individuals were tested for expansions. The STR genotype for the controls
 258 was randomly chosen based on the distributions of these as described in the literature
 259 (Supplemental Table S3). Ten normal, intermediate and expanded alleles were chosen
 260 based on uniform distances between alleles, covering the known normal, intermediate
 261 and expanded allele ranges as described in the literature (Supplementary Table S4);
 262 for autosomal dominant loci, the second allele was chosen randomly with the same
 263 method as the controls. For the recessive STR loci EPM1 and FRDA we sampled two
 264 expanded alleles for individuals with disease. To allow for STR loci assessment on
 265 the X chromosome (FRAXA, FRAXE and SBMA) we generated half of the samples
 266 as male and the other half as female, with males having a single X chromosome and
 267 hence a single STR allele. For the X chromosome STR loci we only investigated the
 268 male individuals. To investigate the effect of control sample size on detection with
 269 exSTRa we sub-sampled the control cohort at intervals of 50, with control cohort
 270 sizes ranging from 50 to 200 individuals. The ART command used to generate the
 271 simulated data was:

272 `art_illumina -i ${file} -p -na -l 150 -f 50 -m 450 -s 50 -o $outfile/$base -1`
 273 `${profiles}/HiSeqXPCRfreeL150R1.txt -2 ${profiles}/HiSeqXPCRfreeL150R2.txt`

274

275 **Performance evaluation**

276 For exSTRa we called individuals as being normal or expanded based on the
 277 Bonferroni multiple testing corrected p-values derived from our empirical p-values.
 278 The number of Bonferroni corrections for the four cohorts was performed based on
 279 the 21 STRs tested per individual for the WGS cohorts and 13 for the WES cohort.
 280 Repeat expansion calls were compared to the known disease status. Performance of
 281 all four methods was evaluated by examining the number of true positives (TP), true
 282 negatives (TN), false positives (FP), false negatives (FN), sensitivity, which is defined
 283 as $TP/(TP+FN)$ and specificity, which is defined as $TN/(TN+FP)$ at each STR and
 284 then summarized across the STR loci, within cohorts.

285

286 **Comparison with ExpansionHunter, STRetch and TREDPARSE**

287 ExpansionHunter¹⁷ estimates the repeat size using a parametric model but does not
 288 attempt to call repeat expansions in a probabilistic framework. ExpansionHunter was
 289 used to determine if alleles were larger than currently known smallest disease-causing
 290 repeat expansion alleles. STRetch was used to detect the presence of repeat expansion
 291 using its statistical test, which is also an outlier detection test. Bonferroni corrections
 292 were calculated as per the exSTRa analysis. TREDPARSE was used to both estimate
 293 the repeat size and to detect the presence of an expansion based on its likelihood
 294 model. Bonferroni corrections were applied in the same way as for exSTRa.

295

296 **Results**

297 **Simulation Study Results**

298 The simulation study of the 20 STR loci provide evidence of the validity and
 299 robustness of the exSTRa test statistic with respect to control cohort size, repeat

expansion size and known expansion status. Decreasing the control cohort in exSTRa showed that results were robust as the control sample size decreased (Supplementary Figure S5). exSTRa also showed consistent results when the size of the repeat expansion allele varied, with longer expansion alleles achieving smaller p-values (Supplementary Figure S4). Overall exSTRa p-values showed adequate Type 1 error, and good discriminatory ability between expansion and non-expansion individuals (Supplementary Figures S3 and S4). The ECDF plots, which are unique to exSTRa, show the effect of increasing expansion size in all STRs, with commensurate right shifts of the distributions. The ECDFs also allow heuristic determination of the genetic model, with larger shifts to the right for the recessive FRDA STR and the X-linked STRs (FRAXA, FRAXE and SBMA). Dominant loci only show the shift in ECDF for the upper half of the ECDF (Supplementary Figure 2). All STR loci performed well for repeat expansion detection in the simulation studies, including FRAXA and FRAXE. The simulated dataset is available to other researchers on request.

315

316 **Coverage and Alignment Results for study cohorts**

Full coverage and alignment results are in Supplemental Table S2 for three cohorts, but not WGS_PF_3, which is described in Dolzhenko et al¹⁷. The median coverage achieved was 44, 66, 82 and 46.3 for cohorts WES, WGS_PCR_1, WGS_PCR_2 and WGS_PF_3 respectively, with 1st and 3rd quartile coverage of (37,48.25), (49.5,71), (76.5,84) and (44.9,47.9) Genome-wide sample specific coverage variability, as measured by the median IQR of the mean coverage library size corrected samples, was very similar between all three WGS_cohorts (WGS_PCR_1 median IQR = 8,

324 WGS_PCR_2 median IQR = 5.7, WGS_PF_3 median IQR = 8.3). In contrast the
325 WES data showed substantial variability (median IQR = 22.3).

326

327 **STR loci sequencing coverage ability**

328 We examined the 21 STR loci for coverage in our four study cohorts. As expected
329 WES_PCR only achieved reasonable coverage for repeat expansion detection in a
330 subset of the STR loci. However, this included many of the known repeat expansion
331 STRs located in coding regions (8 out of 10) (Figure 1 and Supplemental Figure S1).
332 SCA6 (OMIM #183086, *CACNA1A*) and SCA7 (*ATXN7*) are poorly covered. Despite
333 the use of the Agilent SureSelect V5+UTR capture platform, which incorporates
334 UTRs we achieved no, or very low coverage, for the known repeat expansion loci
335 located in the UTR, such as FRAXA (OMIM #300624), FRAXE (OMIM #309548)
336 and DM1 (OMIM #160900). DM1 and SCA7 are not captured by the Agilent
337 enrichment platform (Supplemental Table S3), however both FRAXA and FRAXE
338 are targeted and therefore should be captured. In general, WGS data outperformed
339 WES over all STR loci, with one exception, SCA3 (OMIM #109150), located in the
340 coding region of *ATXN3*. The reason for this is currently unknown.

341

342 **Visualizations of repeat motif distributions**

343 ECDF curves of selected loci are shown for each cohort to illustrate the data. Full
344 results for all 21 loci, for all WGS cohorts, and 10 covered loci for WES cohort, are
345 given in Supplemental Figures S6-S11. STR loci varied in their coverage with several
346 loci consistently poorly captured. These were usually loci that are rich in GC content.
347 Short read NGS data has a known GC bias with a GC content of 40-55% maximizing
348 sequencing yield, depending on sequencing platform.²³ The shape of the ECDF is

349 affected by additional factors such as: the genetic model (dominant, recessive or X-
350 linked) and capture efficiency (for WES).

351

352 The STR loci also showed differences in variability with regards to STR motif
353 lengths. Some STR loci, such as SCA17 (OMIM #607136) and HDL2 (OMIM
354 #606438), showed little variability in STR allele distributions, regardless of NGS
355 platform in our cohorts. Identification of outliers is easier for these loci, with low
356 background variability. Those repeat expansion disorders that are autosomal recessive
357 or X-linked recessive (in males), also show much clearer outlier distributions (Figure
358 2, top right panel). This is due to the outlier distribution deviating for either both
359 alleles, or, in the case of the X-chromosome, and only males, just the one allele
360 having to be examined (not performed in this analysis).

361

362 **Statistical test results for exSTRa**

363 Test statistics were generated for all 21 loci for all N individuals for all four cohorts
364 with exSTRa. Combined p-values over all STR loci for all individuals within each
365 cohort showed approximate uniform distribution with histograms (Supplemental
366 Figure S12) and Q-Q plots (Supplemental Figure S13), albeit with some inflation of
367 p-values at both tails. Our study cohorts had very small numbers of control
368 individuals for some of the cohorts.

369

370 **Expansion call results**

371 Expansion call results are presented in summary form in Tables 3 and 4, and at the
372 individual level in Supplemental table S4 and S5. For the cohorts WES_PCR,
373 WGS_PCR_1, WGS_PCR_2, WGS_PCR_2_30X_1, WGS_PCR_2_30X_2 and

WGS_PF exSTRa achieved sensitivities of 1, 0.67, 0.81, 0.81 and 0.75 and 0.77 respectively, for these cohorts (Table 4), with very high specificity (all cohorts >0.97). Sensitivity is poorly estimated due to the small number of true positives (TPs) in some cohorts, which leads to large variability. This is particularly the case for WES_PCR (4 cases) and WGS_PCR_1 (3 cases). This has also resulted in highly variable results for the other methods. FRAXA was the STR most refractory to analysis, performing poorly regardless of sequencing platform and repeat expansion detection method. Excluding this locus in the evaluation of WGS_PF increased the sensitivity from 0.77 to 0.84, but specificity remained unchanged at 0.97.

383

We divided the WGS_PCR_2 cohort data into two sub-cohorts, where each sample's data comes from a single flow cell lane that has ~30X coverage. This allowed an investigation of reproducibility, and assessment at the more standard 30X coverage. Results were highly reproducible between the two 30X replicates, with only one sample generating an alternative call between the two sequencing runs. We also observed very little change in performance between the 60X and 30X data with virtually identical sensitivity and specificity (Table 4).

391

392 **Comparison with other repeat expansion detection methods**

Across all cohorts (WES_1, WGS_PCR_1, WGS_PCR_2, WGS_PF) exSTRa called the most expansions (79 out of 100 known expansions) compared to ExpansionHunter 75 expansions, STRetch 77 expansions, TREDPARSE-L 52 expansions and TREDPARSE-T 71 expansions, albeit with slightly different results in the REs identified. Excluding FRAXA exSTRa called 71 out of 82 (87%) expansions, ExpansionHunter 74 expansions, STRetch 77 expansions, TREDPARSE-L 51

expansions and TREDPARSE-T 71 expansions each. Notably, exSTRa was able to identify expanded repeats at all eleven STR expansions examined. STRetch was unable to identify the SCA6 expansions in any cohort (N=2 in WGS_PCR_2, N=1 in WGS_PCR_1 and N=1 in WES_1). SCA6 is the shortest of all known repeat expansions. These shorter expansions fail to map preferentially to the decoy chromosome for the most part, leading to the inability to call this locus. This will also apply to other short repeat expansion alleles. However the other methods found most of the SCA6 expansions, regardless of sequencing platform. All four methods performed poorly when analyzing samples with an *FMR1* expansion (FRAXA). In the WGS_PCR_1 and 2 cohorts this is due to poor coverage at the FRAXA and FRAXE loci caused by GC bias issues (Supplemental Figure S1). Although there was a clear right shift of the exSTRa ECDF plots of both the full mutation and premutation *FMR1* samples (Figure 3 bottom left panel), this was not always statistically significant. The other methods similarly performed poorly with this expansion, often failing to detect it. However, ExpansionHunter and TREDPARSE-T and -R identified pre-mutation alleles for this locus ~75% of the time. exSTRa identified 5/15 FRAXA expansions, STRetch identified none and called three of these as SCA3 expansions instead. STRetch performed equal best with ExpansionHunter in the WGS_PF cohort but was the best performer once FRAXA was ignored, finding all remaining repeat expansions, albeit with the highest false positive rate. TREDPARSE and STRetch both perform particularly well for large expansions where their use of “in-repeat reads”^{17; 20}, or reads that map entirely to the repeat, is highly advantageous. exSTRa does not use this information and ExpansionHunter only uses it optionally, for large repeats. Remarkably all four methods call all 13 HD expansions correctly in the WGS_PF_3 cohort (Supplementary Table S5), suggesting highly robust detection of

424 HD expansions for WGS data. The four methods also unanimously identify the
425 SBMA expansion and the two DRPLA expansions.

426

427 exSTRa was the equal best performing method for the WGS_PCR cohorts with
428 TREDPARSE, and performed best overall for the WES cohort. Overall all methods
429 performed more poorly in the WES and WGS_PCR cohorts in comparison to the
430 WGS_PF cohort. exSTRa performs well for small repeat expansions and for
431 platforms where small read fragments have been preferentially selected (WES_PCR,
432 WGS_PCR). Overall the results indicate that no single method is optimal over this
433 breadth of sequencing library preparations and STR loci. These results suggest that a
434 consensus call that makes use of all existing methods could be advantageous.
435 Concordance with at least one other method will be useful to maximize detection of
436 expansions, especially since specificity is high in all WGS cohorts, across all methods
437 (≥ 0.97). This drops to ≥ 0.93 for WES data. Using a rule whereby at least two
438 expansion calls are required, with at least two calling methods showing concordant
439 results to calculate a consensus call, leads to sensitivities of 1 for WES_1, 1 for
440 WGS_PCR_1, 0.81 for WGS_PCR_2 (1, if FRAXA is excluded), 0.77 for
441 WGS_PF_3 and 0.94 for WGS_PF_3 (excluding FRAXA) (Supplementary Tables 4
442 and 5, last columns).

443 Computational expense varied between the different repeat expansion tools. Running
444 time for the WGS_PF cohort comprising 118 samples using 8 CPUs, was
445 approximately 0.5 hours for exSTRa with 10^4 permutations (12.6 hours for 10^6
446 permutations), 0.6 hours for ExpansionHunter, 1.6 hours for TREDPARSE, and 2,300
447 hours for STRetch. STRetch requires that data is realigned to its custom reference

448 genome, which comprises the majority of computation time and also creates
449 additional data storage requirements.

450

451 **Discussion**

452 Genomic medicine, which uses genomic information about an individual as part of
453 their clinical care, promises better patient outcomes and a more efficient health
454 system through rapid diagnosis, early intervention, prevention and targeted therapy.²⁴;

455 ²⁵ A single affordable front-line test that is able to comprehensively detect the genetic
456 basis of human disease is the ultimate goal of diagnostics for genomic medicine and
457 represents the logical way forward in an era of personalized medicine. Screening tests
458 will play a major role in the implementation of preventative medicine.

459

460 Currently, the diagnostic pathway for suspected repeat expansion disorders utilizes
461 single gene tests or small target panels, employing a condition-by-condition approach.
462 This method is cost effective when the clinical diagnosis is straightforward. However,
463 for some disorders, such as spinocerebellar ataxias, the ‘right’ test is not immediately
464 obvious.²⁶ Many families remain unsolved, even after extensive genetic studies
465 encompassing both gene sequencing and expansion repeat testing.²⁶ The
466 implementation of a single NGS-based test that could identify causal point mutations,
467 indels and expanded STRs is likely to be cost effective in this context. NGS-based
468 tests will act as a screening tool, to identify putative expansions, which then need to
469 be followed up with gold-standard methods such as Southern blot analysis or repeat-
470 primed PCR. Pathogenicity will need to be determined by clinical geneticists once
471 the precise make-up of the repeat is determined. SNVs and indels detected in NGS
472 also have to be validated and clinically interpreted. Detecting repeat expansions using

473 NGS-based tests would include both increased diagnostic yield and a reduction in the
474 diagnostic odyssey for many affected individuals.

475

476 Previously described methods such as hipSTR¹⁴, attempt to genotype STRs, i.e.
477 estimate the allele sizes, which renders them ineffective when the repeat size exceeds
478 the read length of the sequencing platform. To address this shortcoming several
479 methods have now been developed that are designed to specifically call repeat
480 expansions. By examining performance using >100 individuals known to have repeat
481 expansions, spanning twelve different repeat expansion disorders, we show that
482 exSTRa, does not require PCR-free library sequencing protocols, nor even WGS, to
483 detect repeat expansions. We show that exSTRa delivers consistent, robust results in
484 simulation studies.

485

486 exSTRa analysis can be run in a self contained cohort of modest size (>15
487 individuals). It does not require any individuals that are known to be unaffected by
488 repeat expansions because it makes use of expanded individuals as ‘controls’ for other
489 loci by using all available data with its robust outlier detection method. exSTRa
490 determines significance of the outlier test statistic by simulation from the cohort using
491 a robust estimator. Hence, the default setting for exSTRa requires that not >15% of
492 individuals in the cohort have the same repeat expansion. exSTRa has a trimming
493 parameter which can be adjusted. Trimming too many observations leads to non-
494 robust results. The default setting is 15%, but this can be increased up to 50% and can
495 be assessed for performance with the ECDF plots. This was applied to the WGS_PF
496 cohort, which had large numbers of FRAXA (56/118, 47%) and FRDA individuals
497 (25/118, 21%). Real disease cohorts, even ascertained from patients with diseases

such as spinocerebellar ataxia, which is known to be enriched for repeat expansions, are highly unlikely to reach >15% contributions from one particular repeat expansion, based on known frequencies of such expansions.

501

We show that exSTRa detected the most repeat expansions across all platforms and STR loci tested. It outperforms other methods at some loci, such as FRAXE, which is the highest frequency Mendelian cause of autism. exSTRa performs well in cohorts with sequencing data with more restrictions on size-fragments and greater PCR artifacts, such as WES and WGS with PCR-based library preparations. Other advantages are that it can be run with fewer requirements (no controls necessary, no size thresholds) and its graphical ECDF representation, which allows QC and fine-tuning of analysis. The exSTRa input file is easily amended to add further loci beyond the 21 investigated. These can be determined by making use of the Tandem Repeat Finder output in the UCSC genome browser. As part of the GitHub exSTRa archive we also supply an additional input file of STRs consisting of a genome wide list of STR loci that are specifically expressed in brain. This file can be amended by the user to target specific areas of the genome, such as regions identified in linkage analysis. In comparison, ExpansionHunter and TREDPARSE (for the threshold model) currently require knowledge of the pathogenic allele size, which will not be known for novel repeat expansion loci. STRetch investigates all STRs listed in its input file simultaneously and uses its novel decoy chromosome method, facilitating genome wide analysis. However this requires re-alignment to an augmented chromosome. We also found that the decoy chromosome method does not perform well with short expansions such as SCA6, since these shorter expanded alleles will preferentially find other sites in the genome, rather than the augmented genome (data not shown).

523 exSTRa does not attempt to call allele sizes, which TREDPARSE, ExpansionHunter
524 and STRetch infer. However, gold standard validation with repeat-primed PCR or
525 Southern blot still needs to occur prior to return of the genetic findings, and these
526 methods size alleles more accurately than the NGS-based methods²⁷.

527

528 We have not investigated the impact of different aligners in detail, but examination of
529 ECDFs from the same cohort but aligned with BWA and Bowtie, the two most
530 commonly used aligners, show highly concordant results. The ability to use existing
531 alignments is a valuable time saving step for STR expansion analysis. exSTRa's
532 ECDF plots inform researchers if re-alignment is necessary or not when batches from
533 different cohorts are combined. Combining cohorts across sequencing platforms is not
534 advisable because motif capture and hence distributions of motif sizes differ between
535 platforms leading to batch effects.

536

537 Some expansion alleles show population heterogeneity in allele sizes, which could
538 influence the inference of expansions with exSTRa, but will also affect other repeat
539 expansion detection methods since they also implicitly assume homogeneity of repeat
540 expansion distributions. One advantage of exSTRa in this context is that the ECDF
541 method allows assessments of the results for such features. If appropriate, population
542 heterogeneity/membership can be assessed with methods such as PLINK²⁸ or
543 PEDDY²⁹, allowing the identification and removal of population outliers or
544 stratification of cohorts. Furthermore the exSTRa ECDF method allows assessments
545 of the results for such features.

546

547 In the context of our results, exSTRa, and the other three methods appear to have
548 potential as a population screening tool for carrier status. For example, all the
549 methods should be able to identify carriers for Friedreich's ataxia, the most prevalent
550 of the inherited ataxias, with a carrier frequency of ~1/100 with high sensitivity and
551 specificity. More broadly, although the current version of exSTRa performed
552 suboptimally for detection of *FMR1* expansions, we believe these limitations can be
553 resolved with further refinements of exSTRa or similar detection methods. Fragile X
554 syndrome (FXS) is the most common cause of inherited ID. Approximately 1/300
555 individuals carry a premutation allele (55-200 repeats) which causes fragile X-
556 associated tremor ataxia syndrome and fragile X primary ovarian insufficiency³⁰.
557 Currently, newborn/carrier screening is not performed for FXS. Historically, there
558 was no medical advantage to early detection of FXS, although recent targeted
559 treatments have shown potential benefits.^{31; 32} There is now discussion regarding the
560 clinical utility of screening *FMR1* for reproductive and personal healthcare.³³

561

562 Given that the genetic basis of disease in many affected individuals currently remains
563 unsolved, even after extensive genetic sequencing, we recommend the introduction of
564 a protocol, such as exSTRa, into any standard sequencing analysis pipeline and that
565 this be run both prospectively and retrospectively. This should identify missed repeat
566 expansions in individuals that have only been tested for a subset of common repeat
567 expansions, which is standard clinical practice, and will also expedite the diagnosis of
568 individuals potentially suffering from a repeat expansion disorder. There are already
569 >20 known repeat expansion loci, but more are likely awaiting discovery. In OMIM
570 there are additional putative SCA loci, such as SCA25 (OMIM #608703, 2p21-p13),

571 with as yet unidentified genetic causes, but which are potentially due to novel
572 pathogenic repeat expansions.

573

574 With large cohorts and further improvements in methodology, we believe methods
575 such as exSTRa and future developments will facilitate the discovery of novel repeat
576 expansion loci, which, in turn, will identify the etiology of neurodegenerative
577 disorders in more affected individuals and families. exSTRa enables fast discovery of
578 repeat expansions in next generation sequencing discovery cohorts including
579 retrospective cohorts consisting mainly of WES data or WGS PCR-free library
580 preparation data. An important new challenge lies in novel repeat expansions that are
581 *de novo*^{4; 5}, and not represented in the reference set of STRs that all four methods
582 need to stipulate at which genomic locations to test. Addressing this current limitation
583 of all RE detection algorithms will require refinement of existing/ the development of
584 new bioinformatics tools.

585

586 The identification of a potentially pathogenic repeat expansion using detection
587 methods such as exSTRa, should not replace the current diagnostic, locus-specific,
588 PCR-based tests. Firstly, these will remain gold-standard, with higher sensitivity and
589 specificity than the sequencing-based methods, and secondly, they give much more
590 accurate estimates of the size of the expanded allele(s), and the makeup of the repeat,
591 including whether there are interruptions, which has prognostic implications for the
592 age of onset, disease progression and outcome.

593

594 We anticipate that there will be further improvements to all of the current methods
595 that identify RE in NGS data. There are clearly sources of bias that affect certain loci

that are contributing to the poor performance at some of the STRs. For instance, we observed a GC bias for the repeat expansion alleles underlying FRAXA, FRAXE and FTDALS1, with far fewer reads able to capture these repeat expansions due to their extreme GC content. Notably FRAXA and FTDALS1 had substantially improved coverage with the PCR-free protocol.

Long read WGS will see further improvements in the detection of repeat expansion alleles, allowing capture of the entire expanded allele in a read fragment, but is currently not cost-effective, being almost 10 times more expensive than the prevailing Illumina HiSeq X sequencing platform. The development of methods such as exSTRa will lead to further improvements in patient care via clinical genomic sequencing. They will also facilitate the pending era of precision/preventative medicine, when screening tests will become much more prevalent. A universal single test will be cost and time effective in comparison to the array of existing tests currently required, to test for all known mutation types.

Appendices

Alignment

Alignment of each pair of FASTQ files was performed with Bowtie2²¹ to the hg19 human genome reference build in very sensitive local mode, with maximum insert sizes of 800 bp for WES samples and 1000 bp for WGS samples. BAM files were sorted and merged with the Novosort tool. Duplicate marking was performed with Picard. Local realignment and base score recalibration was performed with the GATK IndelAligner tool and the Base Quality Score Recalibration tool³⁴ to produce input ready BAM files.

621

622 **Software**

623 The first step of the analysis is performed with a Perl module, called
624 Bio::STR::exSTRa, which carries out a heuristic procedure to extract repeat content.
625 In summary, this procedure uses the data from the reference database for the 21 loci
626 presented in Table 1 to identify all reads that map to each of the STR loci, for each
627 individual to be examined. The number of repeat motifs contained by each read are
628 determined by the heuristic procedure, which examines each read for the repeat units
629 that that STR is known to contain. This allows for some mismatches due to impure
630 repeats and sequencing errors. Additionally, this is more computationally efficient
631 than determining the exact repeat start and end, and is more robust as determining the
632 edge of the repeat can be difficult near the end of a read in the presence of
633 mismatches.

634

635 **Bio::STR::exSTRa : A heuristic procedure to extract repeat units per read**

636 For simplicity, the following description of the data and analysis methods is only for a
637 single locus. The algorithm is repeated independently at each locus.

638

639 Read information is extracted from a database of STR locations, such as 2–6bp repeat
640 unit features generated using the Tandem Repeats Finder³⁵, which is also available as
641 the Simple Repeats track of UCSC Genome Browser. Information is extracted for one
642 STR at a time, with the following algorithm repeated for each STR:

643

644 1. The method identifies ‘anchor’ reads that facilitates identifying reads within or
645 overlapping the STR. To qualify as an anchor, the reads are required to map within

646 800 bp of the STR, with the anchor orientated towards the STR. An anchor may
647 overlap the STR.

648

649 2. The anchor-mate mapping is checked. If the anchor-mate is mapped near the STR
650 and is not overlapping or adjacent, then the read is discarded, while those reads
651 overlapping the STR are taken forward to the next analysis step. Sometimes the read
652 is unmapped, or mapped to another locus, which is then recovered for further
653 interrogation in the next step.

654

655 3. Remaining anchor-mates have their sequence content matched for the presence of
656 the repeat unit in the correct direction, allowing for the repeat to start at any base, or
657 phase, of the repeat unit. For example, if the repeat unit is CAG, the method can also
658 match AGC and GCA. The number of bases found to be part of the repeat unit is
659 counted to derive a repeat-score for that read, that is designated at a given locus as x_{ij}
660 for sample i and read j (note that the maximum defined j depends on the sample). If
661 both ends of a read-pair overlap within an STR, both reads undergo this procedure
662 and each end is given a score that can be resolved during the statistical analysis of the
663 data (the implementation in this paper did not investigate resolving these further, with
664 both ends left in the analysis if any). An example of matching (lower case) a CAG on
665 the opposite strand, thus matching CTG at any starting base, or phase, of the motif,
666 i.e. CTG, TGC and GCT:

667

668 CGTTCAC**ctg**GATGTGAACT**ctg**TC**ctg**ATAGGTCCCC**ctgctgctgctgctgctgctg**Tt
669 **gctgc**TTT**tgctgc**TGT**ctg**AAA

670

671 This 87 bp sequence has 48 bp marked (bold and lower case) as part of the repeat.

672

673 4. The method filters out reads where the score is lower than expected in random
674 nucleotide sequences. While not precisely true, the assumption applied is that the four
675 nucleotides are uniformly distributed and independent with respect to other positions.
676 Short motifs are more likely to appear by chance. The method filters out scores where
677 $x_{ij} < lk/4^k$, where l is the read length and k is the motif length. 800 bp has been chosen
678 to avoid discarding reads overlapping the STR, with the insert size of read pairs
679 having median ~360 bp. Some protocols may need to analyse reads further than 800
680 bp. This can be adjusted when calling the Perl module.

681

682 The output of this Perl module consists of a tab-delimited file consisting of a table
683 where each row in the table is the repeat content of any read from a particular
684 individual that has been identified as mapping to an STR locus that was to be
685 investigated.

686

687 Note that these data do not represent the true size of the allele that the read has
688 captured but where the method predicts an individual with repeat expansion allele at a
689 particular STR locus to show an excess of reads and read content mapping to that
690 STR.

691

692 **R package exSTRa : detecting outlier distributions of repeat content in reads**

693 Analysis methods for the second part of the analysis method are embedded in an R
694 package, called exSTRa (expanded STR algorithm). The output data from step 1 can

695 be loaded and the data visualized. In particular visualizations of the data are
696 performed with empirical cumulative distribution functions, or ECDFs.

697

698 The analysis of the samples is treated as an outlier detection problem. For the N
699 individuals in the cohort the method compares each individual in turn to all others,
700 including itself for robustness, for all STR loci that will be tested for repeat
701 expansions. Since more reads with greater numbers of the repeat motif will be visible
702 in an individual with a repeat expansion at a particular locus, the data at the repeat
703 locus being interrogated is used in a statistical test of a difference of distribution in
704 number of repeats that are observed for a particular individual in comparison to the
705 set of controls. Individuals with an expanded repeat demonstrate a shift in the
706 distribution in comparison to individuals with normal size alleles comprising their
707 genotype for the STR locus being examined. To visualize the results, the output is
708 plotted as empirical cumulative distribution functions (ECDFs) in R.

709

710 Statistical Test

711 We developed a statistical test to detect outlier samples in comparison to a
712 background set of samples. These outlier samples are likely to be individuals
713 harbouring repeat expansions. To apply this test the method utilizes an empirical
714 quantile imputation procedure, implemented in the R function `quantile()`. This
715 function calculates empirical quantiles for any desired probability, for example
716 probability = 0.5 generates the median observation in a dataset, but it is also capable
717 of generating quantiles at probability points that have not been observed, by
718 interpolating the probability distribution function based on the empirical observations.
719 We make use of this function to firstly generate the same number of ‘observations’

for all samples to be tested, defined as M . In general, n is defined so that it is the largest number of observations for all of the samples, but other values could also be chosen, such as the median number of observations. The R function `quantile()` is applied to generate this dataset which consists of N samples, with M observations/quantiles, leading to a dataset with N by M datapoints, or quantiles. This dataset is defined as $Y=(y_{ij})$, where y_{ij} is the repeat content of the j^{th} quantile from the i^{th} individual.

The test statistic, which we call T_i , is defined as the average of multiple t-statistics generated at each quantile j , above a preset threshold $0 \leq h < 1$, which we usually define $h = 0.5$.

$$T_i = \frac{1}{D} \sum_{j: Pr(y_{ij}) \geq h}^M t_{ij}$$

$$D = |\{j : Pr(y_{ij}) \geq h\}|$$

Sixteen of the 21 STR repeat expansion loci to be examined have a dominant mode of inheritance, with only one copy of the expanded allele. This can be observed with the ECDF plots for the autosomal dominant STR loci, where deviations in the repeat composition of reads are only noticeable after the median quantile, when the y-axis (which is the probability) exceeds 0.5. Observations below this threshold are likely to carry no signal, and are thus would not contribute to any test statistic attempting to discriminate between expansions and normal sized alleles.

Each quantile test statistic, t_{ij} , is calculated similarly to a two-sample T-test like test statistic, but using a trimmed mean and variance, to robustly allow for the occurrence of more than one expansion in the background distribution, which is the case in the cohorts we tested but which will also likely be the case in other cohorts. The trimming percentage, or percentage of samples that are used is a parameter that can be set by the user in exSTRa, but the default is set at 0.15. Trimming is performed bilaterally, for both the lower and upper tails of the distributions, resulting in at least 30% of the samples being trimmed.

749

$$t_{ij} = \frac{y_{ij} - m_j}{S_j}$$

$$m_j = \frac{1}{n_j} \sum_{j: l_j \leq y_{ij} \leq u_j} y_{ij}$$

$$n_j = |\{j : l_j \leq y_{ij} \leq u_j\}|$$

$$S_j = s_j \sqrt{1 + \frac{1}{n_j}}$$

750

751

where l_i is the first observation included from the lower tail of the distribution after the trimmed observations and u_i the last observation included from the upper tail of the distribution, with all observations beyond this trimmed. s_j is the sample standard deviation of the trimmed samples.

756

We derive p-values for these test statistics using a simulation procedure.

758

Since the number of individuals in our simulations is not large and only test a single individual, standard permutation tests will not result in sufficient sampling of the

760

empirical distribution thus resulting in a very coarse grained empirical distribution. Instead we take advantage of the well-described empirical distributions of the samples by directly simulating from the background distribution, which represents the distribution of normal, or non-expanded alleles. We perform this using robust methods to ensure that samples with expanded alleles do not influence the simulation in the simulation study.

For simulation s we simulate M quantiles for N samples, by assuming that the distributions at each quantile follow large sample theory and are thus approximately normally distributed with mean m_j and standard deviation d_j , where j denotes the quantile. The method then tests this assumption by performing visual inspections of the distribution of quantiles after standardization with the R function `qqnorm()` and the approximation was reasonable.

The method then uses the median as our estimator for the mean, and the median absolute deviation (MAD) as our robust estimator for the standard deviation. Thus,

$$\hat{m}_j = \text{median}\{y_{\cdot j}\}$$

$$\hat{d}_j = \frac{1}{(\Phi^{-1}(3/4))} \text{MAD}\{y_{\cdot j}\}$$

$$\text{MAD}\{y_{\cdot j}\} = \text{median}\{|y_{ij} - \text{median}\{y_{\cdot j}\}|\}$$

Where Φ , and Φ^{-1} is the inverse of the cumulative distribution function of the standard normal distribution. The R function `mad()` incorporates the scaling factor that ensures consistency with the standard deviation when observations are normally distributed.

783 The method then uses the `rnorm()` function in R to randomly generate the N new
784 observations for each quantile, using the STR locus and quantile specific estimators
785 for the mean and standard deviation. The data is then sorted for each sample, as some
786 of the new observations are no longer monotonically increasing as per definition of
787 quantiles.

788

789 Finally, the test statistic T_s is calculated as defined above, but using the new data set
790 generated from the simulation, where the first sample in the simulated data set is
791 arbitrarily chosen to be the sample to be tested as an outlier. The method then repeat
792 this for a desired number of simulations, say B, and then calculates the empirical p-
793 value for our test statistic using standard methods, where:

794

$$p_{T_i} = \frac{\sum_{s=1}^B I([T_i > T_1^s]) + 1}{B + 1}$$

795

796 Here $I(.)$ is the indicator function. T_1^S is the test statistic for the dataset. The method
797 calls individuals as expanded or not for each STR locus examined based on a
798 Bonferroni corrected threshold at the 0.05 significance level, based on the number of
799 STR tested for each sample.

800

801 Standard deviations for the empirical p-value estimator were also calculated as
802 follows.

$$SD(\hat{p}) = \sqrt{\frac{1 + \sum_{i=1}^B x_i (1 - \frac{\sum_{i=1}^B x_i}{B+1})}{B}}$$

$$x_i = I([T_i > T_1^S])$$

803

804 **Calling expansions with ExpansionHunter, STRetch and TREDPARSE**

We performed analysis with ExpansionHunter (version 2.5.3), STRetch (GitHub commit 94d0516) and TREDPARSE (GitHub commit 83881b4), on the cohorts at the 21 repeat expansion loci listed in Table 1. The input data was the same BAM files generated as described above. Only specification files (in JSON format) for the DM1, DRPLA, FRAXA, FRDA, FTDALS1, HD, SBMA, SCA1 and SCA3 loci were provided with ExpansionHunter. The JSON files for the remaining loci were obtained by personal communication with Egor Dolzhenko (Illumina, Inc. San Diego, CA, USA). For data aligned with bowtie2, the --min-anchor-mapq parameter was set to 44, while for the original alignments of the Coriell samples this parameter was set to 60. The --read-depth parameter was set the median coverage for each sample in the WES_PCR cohort, otherwise this was computed by ExpansionHunter for the WGS samples. The list of STR loci provided with STRetch does not include FRDA, which was added manually. The EPM1 repeat motif is 12 bp and is not assessed using STRetch, which aligns to an augmented reference genome containing a decoy chromosome for each STR repeat motif up to 6 bp in size.

820

ExpansionHunter and TREDPARSE-T call allele lengths and genotypes. To call individuals as having expansions requires the user to define thresholds on allele sizes as to what constitutes an appropriate threshold. For FRAXA, we additionally tested using the premutation threshold (labelled FRAXA_pre), in addition to testing for full expansions. To call an expansion, we used the same thresholds as Dolzhenko et al¹⁷ (based on McMurray³⁶) or the largest reported normal allele size at other loci. Other thresholds will change the sensitivity and specificity. TREDPARSE-L expansions calls were recorded for all samples labelled as “risk”. exSTRa p-values were Bonferroni corrected over the number of STRs tested. STRetch reports p-values

adjusted for multiple testing over all STRs genome wide, however unadjusted p-values were extracted and Bonferroni corrected over just the number of STRs tested. A threshold of $p < 0.05$ was used for significance.

Supplemental Data

Supplemental Data includes 13 figures and 5 tables.

Acknowledgements

We would like to thank Egor Dolzhenko and Michael Eberle (Illumina Inc), who produced the STR specification files for ExpansionHunter and gave access to the EGA00001003562. We thank Leslie Burnett, Ben Lundie, Katie Ayres and Andrew Sinclair for access to control datasets. We thank Kate Pope and Greta Gillies for assistance with recruitment and sample preparation.

RT was supported by an Australian Postgraduate Award and funding from the Edith Moffat fund. PJJ was supported by NHMRC CDA2 (GNT1032364). MB was supported by NHMRC Program Grant (GNT1054618) and NHMRC Senior Research Fellowship (APP1102971). This work was supported by the Victorian Government's Operational Infrastructure Support Program and Australian Government National Health and Medical Research Council Independent Research Institute Infrastructure Support Scheme (NHMRC IRIISS).

Web Resources

exSTRa <http://github.com/bahlolab/exSTRa>

ExpansionHunter <https://github.com/Illumina/ExpansionHunter>

855 TREDPARSE <https://github.com/humanlongevity/tredparse>

856 STRetch <https://github.com/Oshlack/STRetch>

857 Picard <http://broadinstitute.github.io/picard/>

858 Novosort <http://www.novocraft.com/products/novosort/>

859 OMIM <https://www.omim.org>

860 GATK IndelAligner <https://software.broadinstitute.org/gatk/>

861 Coriell <https://www.coriell.org/>

862

863 **Figure Legends**

864

865 **Figure 1** ECDF of repeat expansion composition of reads from the WES cohort,
 866 depicting four different known repeat expansion disorders captured by WES (HD,
 867 SCA2, SCA6 and SCA1). Sample rptWEHI3 (blue) is a known HD repeat expansion
 868 patient. The expanded allele size is not known. Sample rptWEHI1 (yellow) a known
 869 SCA2 repeat expansion of length 42 repeats, sample rptWEHI2 (red) a known SCA6,
 870 of length 22 repeats, and sample rptWEHI4 (green) a known SCA1 patient, of length
 871 52 repeats. The title at the top of each individual figure gives the locus being
 872 examined, the reference number of repeats in the hg19 human genome reference with
 873 the corresponding number of bps, and the smallest reported expanded allele in the
 874 literature (with the corresponding number of bps in brackets). The blue dashed
 875 vertical line in the plot denotes the largest known normal allele, the red dashed
 876 vertical line denotes the smallest known expanded allele.

877

878 **Figure 2** ECDFs of repeat expansion composition of reads from the WGS_PCR_2
 879 cohort, depicting four different STR loci (top left = SCA1, length of the expanded

alleles are 52 and 45 repeats; top right = FRDA, length of the expanded alleles are 320 and 788 repeats; bottom left = SCA7, length of the expanded allele is 39; bottom right = DM1, length of the expanded alleles are 173 and 83 repeats). Here coloured samples at each STR indicate those called by exSTRa as repeat expansions at the STR locus. The title at the top of each individual figure gives the locus being examined, the reference number of repeats in the hg19 human genome reference with the corresponding number of bps, and the smallest reported expanded allele in the literature (with the corresponding number of bps in brackets). The blue dashed vertical line in the plot denotes the largest known normal allele, the red dashed vertical line denotes the smallest known expanded allele.

890

Figure 3. ECDFs for four repeat expansion loci from WGS_PF_3 cohort .Top left, DM1; top right, FRDA; bottom left, FRAXA; bottom right, HD .The title at the top of each individual figure gives the locus being examined, the reference number of repeats in the hg19 human genome reference with the corresponding number of bps, and the smallest reported expanded allele in the literature (with the corresponding number of bps in brackets). The blue dashed vertical line in the plot denotes the largest known normal allele, the red dashed vertical line denotes the smallest known expanded allele.

899

900 **Table Legends**

Table 1 Detailed STR loci information. TRF = Tandem Repeats Finder (Benson et al, 1999). TRF match and TRF indel describe the purity of the repeat. AD = autosomal dominant, X = X-linked, AR = autosomal recessive.

904

905 **Table 2** Repeat type, genetic model, diseases, sample names and which cohorts
 906 samples appear in. Allele sizes are derived from standard laboratory tests for repeat
 907 expansions. Some individuals were not tested (Not sized) or the data was not
 908 available (not recorded). MOI, mode of inheritance; AD, autosomal dominant; X, X-
 909 linked, AR; autosomal recessive. Only the total number of controls are given denoted
 910 by (controls).

911 **Table 3** Repeat Expansion detection results for exSTRa, ExpansionHunter, STRetch
 912 and TREDPARSE over all four cohorts. TP, true positive; FN, false negative; FP,
 913 false positive; TN, true negative, Sensitivity, $TP/(TP+FN)$; Specificity, $TN/(FP+TN)$;
 914 NA, not applicable. WES cohort labeled with (*) only assessed over eleven STR loci
 915 in the capture design. WGS_PCR_2 was also analysed split into two sub-cohorts, split
 916 by flow cell lane, and are designated as WGS_PCR_2_30X_1 and
 917 WGS_PCR_2_30X_2.

918

919

920

921

922

Disease	Symbol	OMIM	Inheritance	Gene	Cytogenetic Location	Type	Repeat Motif	Normal Range	Expansion Range	Strand	Start hg19	Reference Repeat Number	TRF Match (%)	TRF Indel (%)	Reference STR size (bp)
Huntington disease	HD	143100	AD	<i>HTT</i>	4p16.3	Coding	CAG	6-34	36-100+	+	3,076,604	21.3	96	0	64
Kennedy disease	SBMA	313200	X	<i>AR</i>	Xq12	Coding	CAG	9-35	38-62	+	66,765,159	33.3	86	9	103
Spinocerebellar ataxia 1	SCA1	164400	AD	<i>ATXN1</i>	6p23	Coding	CAG	6-38	39-82	-	16,327,865	30.3	95	0	91
Spinocerebellar ataxia 2	SCA2	183090	AD	<i>ATXN2</i>	12q24	Coding	CAG	15-24	32-200	-	112,036,754	23.3	97	0	70
Machado-Joseph disease	SCA3	109150	AD	<i>ATXN3</i>	14q32.1	Coding	CAG	13-36	61-84	-	92,537,355	14	84	0	42
Spinocerebellar ataxia 6	SCA6	183086	AD	<i>CACNA1A</i>	19p13	Coding	CAG	4-7	21-33	-	13,318,673	13.3	100	0	40
Spinocerebellar ataxia 7	SCA7	164500	AD	<i>ATXN7</i>	3p14.1	Coding	CAG	4-35	37-306	+	63,898,361	10.7	100	0	32
Spinocerebellar ataxia 17	SCA17	607136	AD	<i>TBP</i>	6q27	Coding	CAG	25-42	47-63	+	170,870,995	37	94	0	111
Dentatorubral-pallidolusian atrophy	DRPLA	125370	AD	<i>DRPLA/ATN1</i>	12p13.31	Coding	CAG	7-34	49-88	+	7,045,880	19.7	92	0	59
Huntington disease-like 2	HDL2	606438	AD	<i>JPH3</i>	16q24.3	Exon	CTG	7-28	66-78	+	87,637,889	15.3	95	4	47
Fragile-X site A	FRAXA	300624	X	<i>FMR1</i>	Xq27.3	5'UTR	CGG	6-54	200-1000+	+	146,993,555	25	90	5	75
Fragile-X site E	FRAXE	309548	X	<i>FMR2</i>	Xq28	5'UTR	CCG	4-39	200-900	+	147,582,159	15.3	100	0	46
Myotonic dystrophy 1	DM1	160900	AD	<i>DMPK</i>	19q13	3'UTR	CTG	5-37	50-10000	-	46,273,463	20.7	100	0	62
Friedreich ataxia	FRDA	229300	AR	<i>FXN</i>	9q13	Intron	GAA	6-32	200-1700	+	71,652,201	6.7	100	0	20
Myotonic dystrophy 2	DM2	602668	AD	<i>ZNF9/CNBP</i>	3q21.3	Intron	CCTG	10-26	75-11000	-	128,891,420	20.8	92	0	83

Frontotemporal dementia and/or amyotrophic lateral sclerosis 1	FTDALS1	105550	AD	<i>C9orf72</i>	9p21	Intron	GGGGCC	2-19	250-1600	-	27,573,483	10.8	74	8	62
Spinocerebellar ataxia 36	SCA36	614153	AD	<i>NOP56</i>	20p13	Intron	GGCCTG	3-8	1500-2500	+	2,633,379	7.2	97	0	43
Spinocerebellar ataxia 10	SCA10	603516	AD	<i>ATXN10</i>	22q13.31	Intron	ATTCT	10-20	500-4500	+	46,191,235	14	100	0	70
Myoclonic epilepsy of Unverricht and Lundborg	EPM1	254800	AR	<i>CSTB</i>	21q22.3	Promoter	CCCCGCC	2-3	40-80	-	45,196,324	3.1	100	0	37
Spinocerebellar ataxia 12	SCA12	604326	AD	<i>PPP2R2B</i>	5q32	Promoter	CAG	7-45	55-78	-	146,258,291	10.7	100	0	32
Spinocerebellar ataxia 8	SCA8	608768	AD	<i>ATXN8OS/ATXN8</i>	13q21	utRNA	CTG	16-34	74+	+	70,713,516	15.3	100	0	46
Spinocerebellar ataxia 31	SCA31	117210	AD	<i>BEAN1/TK2</i>	16q21	Intron	TGGAA ^a	0	2.5-3.8kb ^b	+	66,524,302	0	N/A	N/A	N/A
Spinocerebellar ataxia 37	SCA37	615945	AD	<i>DAB1</i>	1p32.3	Intron	ATTTC ^a	0	31-75	-	57,832,716 ^c	0	N/A	N/A	N/A
Familial adult myoclonic epilepsy 1 ^e	FAME1/ BAFME1	601068	AD	<i>SAMD12</i>	8q24	Intron	TTTCA ^a	0	440-3,680 ^f	-	119,379,055 ^d	0	N/A	N/A	N/A

923 **Table 1 Short tandem repeat loci information for STRs causing neurogenetic disorders.** TRF, Tandem Repeats Finder (Benson et al, 1999). TRF match and TRF indel
924 describe the purity of the repeat. AD, autosomal dominant; X, X-linked; AR, autosomal recessive; UTR, untranslated region. ^aThese repeat expansions are novel insertions
925 and thus not represented in the reference genome at their respective locations. ^bSCA31 is caused by the insertion of a complex repeat containing (TGGAA)_n; hence the
926 length is given in as the length of the expanded repeats in bps, instead of repeat number. ^cThe SCA37 physical map location is given at the reference (ATTTT)_n repeat,
927 where affected individuals have the pathogenic (ATTTC)_n inserted. ^dThe FAME1 physical map location is given as the position of the reference (TTTTA)_n repeat, at which

928 affected individuals have (TTTCA)_n inserted. ^eIshiura et al. identified similar expansions associatioaed with FAME6 and FAME7, in the genes TNRC6A and RAPGEF2
 929 respectively, but only in single families. These have not been listed. ^fThe FAME1 repeat size is the estimated size of the combined expanded (TTTCA)_n and the (TTTTA)_n
 930 reference repeat.

931

932	Class	MOI	Diagnosis	Allele sizes	Gender	WES_PCR	WGS_PCR_1	WGS_PCR_2
933	PolyQ	AD	HD	Not recorded	male	rptWEHI3	HD-1	
934	PolyQ	AD	HD	17,39	female			WGSrpt_10
935	PolyQ	AD	HD	20,42	male			WGSrpt_12
936	PolyQ	AD	SCA1	36,52	female	rptWEHI4		WGSrpt_14
937	PolyQ	AD	SCA1	30,45	male			WGSrpt_16
938	PolyQ	AD	SCA2	21,42	female	rptWEHI1	SCA2-1	WGSrpt_18
939	PolyQ	AD	SCA2	23,39	male			WGSrpt_20
940	PolyQ	AD	SCA6	11,22	female	rptWEHI2	SCA6-1	WGSrpt_05
941	PolyQ	AD	SCA6	10,21	female			WGSrpt_07
942	PolyQ	AD	SCA7	13,39	female			WGSrpt_08
943	5'UTR	X	FRAXA	Not sized	male			WGSrpt_17
944	5'UTR	X	FRAXA	613-1680	male			WGSrpt_19
945	5'UTR	X	FRAXA (pre)	~100	female			WGSrpt_21
946	3'UTR	AD	DM1	8,173	female			WGSrpt_13
947	3'UTR	AD	DM1	13,83	male			WGSrpt_15
948	Intron	AR	FRDA	320,320	male			WGSrpt_09
949	Intron	AR	FRDA	788,788	male			WGSrpt_11
950			(controls)			58	14	2
951								

Table 2. Repeat type, genetic model, diseases, sample names and which cohorts samples appear in. Allele sizes are derived from standard laboratory tests for repeat expansions. Some individuals were not tested (Not sized) or the data was not available (not recorded). MOI = mode of inheritance (AD = autosomal dominant, X = X-linked, AR = autosomal recessive). Only the total number of controls are given denoted by (controls).

Class	MOI	Diagnosis	Expanded Affected		Not Expanded
PolyQ	AD	HD	13	13	105
PolyQ	AD	SCA1	3	3	115
PolyQ	AD	SCA3	1	1	117
PolyQ	AD	DRPLA	2	2	116
PolyQ	AD	SBMA	1	1	117
5'UTR	X	FRAXA	16	16	102
5'UTR	X	FRAXA (pre)	33	21	85
3'UTR	AD	DM1	17	17	101
Intron	AR	FRDA	25	14	93
		Total (FRAXA) ^a	78		40
		Total (FRAXA pre)	95		23

Table 3 WGS_PF cohort. Cohort of 118 individuals sequenced with Illumina PCR-free library preparation. Only total number of samples are listed, rather than actual samples. Details of samples are available in Dolzhenko et al 2017. ^aTotal only includes FXS individuals, and no intermediate pre expansions.

	Cohort	Cases	Controls[^]	Method	TP	FN	TN	FP	Sensitivity	Specificity
971										
972	WES_PCR*	4	58	exSTRa	4	0	607	9	1	0.99
973				ExpansionHunter	2	2	616	0	0.5	1
974				STRetch ^a	3	1	613	3	0.75	1
975				TREDPARSE-T ^b	4	0	585	31	1	0.95
976				TREDPARSE-L ^b	4	0	574	42	1	0.93
977	WGS_PCR_1	3	14	exSTRa	2	1	343	11	0.67	0.97
978				ExpansionHunter	3	0	354	0	1	1
979				STRetch ^a	1	2	336	1	0.33	1
980				TREDPARSE-T ^b	3	0	354	0	1	1
981				TREDPARSE-L ^b	3	0	354	0	1	1
982	WGS_PCR_2	16	2	exSTRa	13	3	352	10	0.81	0.97
983				ExpansionHunter	8	8	362	0	0.5	1
984				STRetch ^a	11	5	338	6	0.69	0.98
985				TREDPARSE-T ^b	12	4	362	0	0.75	1
986				TREDPARSE-L ^b	11	5	362	0	0.69	1
987	WGS_PCR_2_30X_1	16	2	exSTRa	13	3	357	5	0.81	0.99
988				ExpansionHunter	8	8	362	0	0.5	1
989				STRetch ^a	11	5	340	4	0.69	0.99
990				TREDPARSE-T ^b	13	3	362	0	0.81	1
991				TREDPARSE-L ^b	9	7	362	0	0.56	1
992	WGS_PCR_2_30X_2	16	2	exSTRa	12	4	354	8	0.75	0.98
993				ExpansionHunter	8	8	362	0	0.5	1

994				STRetch ^a	11	5	336	8	0.69	0.98
995				TREDPARSE-T ^b	13	3	362	0	0.81	1
996				TREDPARSE-L ^b	10	6	362	0	0.62	1
997	WGS_PF	77	41	exSTRa	60	17	2330	71	0.78	0.97
998		77	41	ExpansionHunter ^c	62	15	2395	6	0.81	1
999		96	22	EH FRAXA_pre ^d	95	1	2374	8	0.99	1
1000		96	22	STRetch ^a	62	15	2207	76	0.81	0.97
1001		96	22	TREDPARSE-T ^b	52	25	2384	17	0.68	0.99
1002		96	22	TP-T FRAXA_pre ^d	72	24	2364	18	0.75	0.99
1003		66	52	TREDPARSE-L ^b	34	32	2396	16	0.52	0.99
1004		72	46	TP-L FRAXA_pre ^d	48	24	2383	23	0.67	0.99
1005	WGS_PF (no FRAXA)	62	56	exSTRa	52	10	2231	67	0.84	0.97
1006				ExpansionHunter ^c	61	1	2292	6	0.98	1
1007				STRetch ^a	62	0	2104	76	1	0.97
1008				TREDPARSE-T ^b	52	10	2281	17	0.84	0.99
1009		51	67	TREDPARSE-L ^b	34	17	2293	16	0.67	0.99

1010 **Table 4 Repeat expansion detection results for all four cohorts. ^Individuals designated as controls have no known repeat expansions. Individuals designated as cases**
1011 **have one known repeat expansion, but are controls for all other loci tested. TP, true positive; FN, false negative, TN, true negative; FP, false positive; Sensitivity,**
1012 **TP/(TP+FN); Specificity, TN/(FP+TN); WES cohort labeled with (*) only assessed over ten STR loci in the capture design. WGS_PCR_2 was also analysed split into two sub-**
1013 **cohorts, split by flow cell lane, and are designated as WGS_PCR_2_30X_1 and WGS_PCR_2_30X_2.^STRetch was Bonferroni corrected for the same number of tests as the**
1014 **other methods, and not genome-wide corrected. ^bTREDPARSE results are given for the repeat expansion size threshold method (TREDPARSE-T) and for the likelihood**
1015 **ratio test based method (TREDPARSE-L). For STR loci with recessive inheritance, samples with double expansions were designated as cases for TREDPARSE-L, which**

1016 takes into account the inheritance model. ^cFor the WGS_PF cohort the original ExpansionHunter results from Dolzhenko et al were used, which make use of reads aligned
1017 with a different aligner. ^dFor the WGS_PF cohort, additional results were computed using the premutation threshold to test for FRAXA expansions with ExpansionHunter
1018 (EH FRAXA_pre), TREDPARSE-T (TP-T FRAXA_pre) and TREDPARSE-L (TP-L FRAXA_pre).

1019

1020 **References**

- 1021 1. Benson, G. (1999). Tandem repeats finder: a program to analyze DNA sequences.
1022 Nucleic Acids Res 27, 573-580.
- 1023 2. Jones, L., Houlden, H., and Tabrizi, S.J. (2017). DNA repair in the trinucleotide
1024 repeat disorders. The Lancet Neurology 16, 88-96.
- 1025 3. Hannan, A.J. (2018). Tandem repeats mediating genetic plasticity in health and
1026 disease. Nat Rev Genet, 1-13.
- 1027 4. Seixas, A.I., Loureiro, J.R., Costa, C., Ordóñez-Ugalde, A., Marcelino, H.,
1028 Oliveira, C.L., Loureiro, J.L., Dhingra, A., Brandão, E., Cruz, V.T., et al.
1029 (2017). A Pentanucleotide ATTTTC Repeat Insertion in the Non-coding Region
1030 of DAB1 , Mapping to SCA37 , Causes Spinocerebellar Ataxia. The American
1031 Journal of Human Genetics 101, 87-103.
- 1032 5. Ishiura, H., Doi, K., Mitsui, J., Yoshimura, J., Matsukawa, M.K., Fujiyama, A.,
1033 Toyoshima, Y., Kakita, A., Takahashi, H., Suzuki, Y., et al. (2018).
1034 Expansions of intronic TTTC and TTTTA repeats in benign adult familial
1035 myoclonic epilepsy. Nat Genet, 1-14.
- 1036 6. Schulz, J.B., Boesch, S., Bürk, K., Durr, A., Giunti, P., Mariotti, C., Pousset, F.,
1037 Schöls, L., Vankan, P., and Pandolfo, M. (2009). Diagnosis and treatment of
1038 Friedreich ataxia: a European perspective. Nat Rev Neurol 5, 222-234.
- 1039 7. Seltzer, M.M., Baker, M.W., Hong, J., Maenner, M., Greenberg, J., and Mandel, D.
1040 (2012). Prevalence of CGG expansions of the FMR1 gene in a US population-
1041 based sample. Am J Med Genet B Neuropsychiatr Genet 159B, 589-597.
- 1042 8. Tassone, F. (2014). Newborn screening for fragile X syndrome. JAMA Neurol 71,
1043 355-359.


- 1044 9. Genetic Modifiers of Huntington's Disease, C. (2015). Identification of Genetic
1045 Factors that Modify Clinical Onset of Huntington's Disease. *Cell* 162, 516-
1046 526.
- 1047 10. Bettencourt, C., Hensman Moss, D.J., Flower, M., Wiethoff, S., Brice, A., Goizet,
1048 C., Stevanin, G., Koutsis, G., Karadima, G., Panas, M., et al. (2016). DNA
1049 repair pathways underlie a common genetic mechanism modulating onset in
1050 polyglutamine diseases. *Ann Neurol*.
- 1051 11. Németh, A.H., Kwasniewska, A.C., Lise, S., Parolin Schnekenberg, R., Becker,
1052 E.B.E., Bera, K.D., Shanks, M.E., Gregory, L., Buck, D., Zameel Cader, M.,
1053 et al. (2013). Next generation sequencing for molecular diagnosis of
1054 neurological disorders using ataxias as a model. *Brain* 136, 3106-3118.
- 1055 12. Tae, H., Kim, D.-Y., McCormick, J., Settlage, R.E., and Garner, H.R. (2014).
1056 Discretized Gaussian mixture for genotyping of microsatellite loci containing
1057 homopolymer runs. *Bioinformatics* 30, 652-659.
- 1058 13. Gymrek, M., Golan, D., Rosset, S., and Erlich, Y. (2012). lobSTR: A short
1059 tandem repeat profiler for personal genomes. *22*, 1154-1162.
- 1060 14. Willems, T., Zielinski, D., Yuan, J., Gordon, A., Gymrek, M., and Erlich, Y.
1061 (2017). Genome-wide profiling of heritable and de novo STR variations. *Nat*
1062 *Methods* 14, 590-592.
- 1063 15. Highnam, G., Franck, C., Martin, A., Stephens, C., Puthige, A., and Mittelman, D.
1064 (2013). Accurate human microsatellite genotypes from high-throughput
1065 resequencing data using informed error profiles. *Nucleic Acids Res* 41, e32.
- 1066 16. Cao, M.D., Tasker, E., Willadsen, K., Imelfort, M., Vishwanathan, S.,
1067 Sureshkumar, S., Balasubramanian, S., and Boden, M. (2013). Inferring short

- 1068 tandem repeat variation from paired-end short reads. *Nucleic Acids Res* 42, p.
1069 e16.
- 1070 17. Dolzhenko, E., van Vugt, J.J.F.A., Shaw, R.J., Bekritsky, M.A., van Blitterswijk,
1071 M., Narzisi, G., Ajay, S.S., Rajan, V., Lajoie, B., Johnson, N.H., et al. (2017).
1072 Detection of long repeat expansions from PCR-free whole-genome sequence
1073 data. *Genome Res* 27, 1895-1903.
- 1074 18. Dashnow, H., Lek, M., Phipson, B., Halman, A., Davis, M., Lamont, P., Laing,
1075 N., MacArthur, D., and Oshlack, A. (2017). STRetch: detecting and
1076 discovering pathogenic short tandem repeats expansions. *bioRxiv*.
- 1077 19. Tang, H., Kirkness, E.F., Lippert, C., Biggs, W.H., Fabani, M., Guzman, E.,
1078 Ramakrishnan, S., Lavrenko, V., Kakaradov, B., Hou, C., et al. (2017).
1079 Profiling of Short-Tandem-Repeat Disease Alleles in 12,632 Human Whole
1080 Genomes. *Am J Hum Genet* 101, 700-715.
- 1081 20. Bahlo, M., Bennett, M.F., Degorski, P., Tankard, R.M., Delatycki, M.B., and
1082 Lockhart, P.J. (2018). Recent advances in the detection of repeat expansions
1083 with short-read next-generation sequencing. *F1000Res* 7, 736.
- 1084 21. Langmead, B., Trapnell, C., Pop, M., Salzberg, S., Langmead, B., Trapnell, C.,
1085 Pop, M., and Salzberg, S. (2009). Ultrafast and memory-efficient alignment of
1086 short DNA sequences to the human genome. In *Genome Biol.* p R25.
- 1087 22. Huang, W., Li, L., Myers, J.R., and Marth, G.T. (2012). ART: a next-generation
1088 sequencing read simulator. *Bioinformatics* 28, 593-594.
- 1089 23. Benjamini, Y., and Speed, T.P. (2012). Summarizing and correcting the GC
1090 content bias in high-throughput sequencing. *Nucleic Acids Res* 40, e72.
- 1091 24. Rehm, H.L. (2017). Evolving health care through personal genomics. *Nat Rev*
1092 *Genet* 18, 259-267.


- 1093 25. Ashley, E.A. (2015). The precision medicine initiative: a new national effort.
1094 JAMA 313, 2119-2120.
- 1095 26. Nemeth, A.H., Kwasniewska, A.C., Lise, S., Parolin Schnekenberg, R., Becker,
1096 E.B.E., Bera, K.D., Shanks, M.E., Gregory, L., Buck, D., Zameel Cader, M.,
1097 et al. (2013). Next generation sequencing for molecular diagnosis of
1098 neurological disorders using ataxias as a model. In Brain. (
- 1099 27. Mousavi, N., Shleizer-Burko, S., and Gymrek, M. (2018). Profiling the genome-
1100 wide landscape of tandem repeat expansions. bioRxiv.
- 1101 28. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A.R., Bender, D.,
1102 Maller, J., Sklar, P., de Bakker, P.I.W., Daly, M.J., et al. (2007). PLINK: a
1103 tool set for whole-genome association and population-based linkage analyses.
1104 Am J Hum Genet 81, 559-575.
- 1105 29. Pedersen, B.S., and Quinlan, A.R. (2017). Who's Who? Detecting and Resolving
1106 Sample Anomalies in Human DNA Sequencing Studies with Peddy. Am J
1107 Hum Genet 100, 406-413.
- 1108 30. Hunter, J., Rivero-Arias, O., Angelov, A., Kim, E., Fotheringham, I., and Leal, J.
1109 (2014). Epidemiology of fragile X syndrome: a systematic review and meta-
1110 analysis. Am J Med Genet 164A, 1648-1658.
- 1111 31. Ligsay, A., and Hagerman, R.J. (2016). Review of targeted treatments in fragile X
1112 syndrome. Intractable Rare Dis Res 5, 158-167.
- 1113 32. Hagerman, R.J., and Polussa, J. (2015). Treatment of the psychiatric problems
1114 associated with fragile X syndrome. Curr Opin Psychiatry 28, 107-112.
- 1115 33. Hagerman, R., and Hagerman, P. (2013). Advances in clinical and molecular
1116 understanding of the FMR1 premutation and fragile X-associated
1117 tremor/ataxia syndrome. The Lancet Neurology 12, 786-798.

- 1118 34. DePristo, M.A., Banks, E., Poplin, R., Garimella, K.V., Maguire, J.R., Hartl, C.,
1119 Philippakis, A.A., del Angel, G., Rivas, M.A., Hanna, M., et al. (2011). A
1120 framework for variation discovery and genotyping using next-generation DNA
1121 sequencing data. Nat Genet 43, 491-498.
- 1122 35. Benson, G. (1999). Tandem repeats finder: a program to analyze DNA sequences.
1123 In Nucleic Acids Res. pp 573-580.
- 1124 36. McMurray, C.T. (2010). Mechanisms of trinucleotide repeat instability during
1125 human development. Nat Rev Genet 11, 786-799.
- 1126
- 1127


DM1 (3'UTR CTG) norm: 20 (62bp) , exp: 50 (150bp) score ECDF




FRDA (intron_1 GAA) norm: 6 (20bp) , exp: 200 (600bp) score ECDF







FRAXA (5'UTR CGG) norm: 25 (75bp) , exp: 200 (600bp) score ECDF




HD (coding CAG) norm: 21 (64bp) , exp: 36 (108bp) score ECDF







SCA1 (coding CAG) norm: 30 (91bp) , exp: 39 (117bp) score ECDF



FRDA (intron_1 GAA) norm: 6 (20bp) , exp: 200 (600bp) score ECDF



SCA7 (coding CAG) norm: 10 (32bp) , exp: 37 (111bp) score ECDF



DM1 (3'UTR CTG) norm: 20 (62bp) , exp: 50 (150bp) score ECDF

